

MAR 24 2010

Amendments to the Claims**1-40. (Cancelled)**

**41. (Currently amended)** An aqueous liquid preparation consisting essentially of at least the following two components, wherein the first component ~~comprising~~ is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component ~~comprising~~ is an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, wherein said liquid preparation is formulated for ophthalmic administration.

**42. (Currently amended)** The aqueous liquid preparation according to claim 41, wherein the ~~alkyl aryl polyether alcohol type polymer~~ second component is tyloxapol;  
~~wherein the concentration of the tyloxapol is selected from a range of about 0.01 w/v %~~  
~~to about 0.5 w/v %; and~~  
~~wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is selected from a range of about 0.01 to about 0.5 w/v %.~~

**43. (Currently amended)** The aqueous liquid preparation according to claim ~~42~~41, wherein the first component is ~~pharmacologically acceptable salt of a~~ 2-amino-3-(4-bromobenzoyl)phenylacetic acid ~~is a sodium salt.~~

**44. (Currently amended)** The aqueous liquid preparation according to claim ~~43~~41, wherein the second component is tyloxapol and the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt, wherein the concentration of the tyloxapol is from about 0.01 w/v % to about 0.5 w/v %; and  
wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.5 w/v %

~~2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is selected from a range of about 0.05 to about 0.2 w/v %.~~

**45. (Currently amended)** The aqueous liquid preparation according to claim 44, wherein the concentration of the tyloxapol is ~~selected from a range of~~ about 0.01 w/v % to about 0.3 w/v % and the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 to about 0.2 w/v %.

**46. (Previously presented)** The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

**47. (Currently amended)** The aqueous liquid preparation according to claim ~~46~~45, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**48. (Currently amended)** The aqueous liquid preparation according to claim ~~47~~41, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**49. (Previously presented)** The aqueous liquid preparation according to claim 48, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**50. (Previously presented)** The aqueous liquid preparation according to claim 49, wherein the pH is from about 7 to about 9.

**51. (Currently amended)** The aqueous liquid preparation according to claim ~~50~~49, wherein the pH is from about 7.5 to about 8.5.

**52. (Cancelled)**

**53. (Previously presented)** The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

**54. (Currently amended)** The aqueous liquid preparation according to claim 53~~45~~, wherein the concentration of the tyloxapol is about 0.3 w/v %.

**55. (Previously presented)** The aqueous liquid preparation according to claim 54, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**56. (Previously presented)** The aqueous liquid preparation according to claim 55, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**57. (Cancelled)**

**58. (Previously presented)** The aqueous liquid preparation according to claim 53, wherein the concentration of the tyloxapol is about 0.02 w/v %.

**59. (Previously presented)** The aqueous liquid preparation according to claim 58, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

**60. (Previously presented)** The aqueous liquid preparation according to claim 59, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

**61. (Withdrawn-Currently amended)** A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, to obtain an aqueous liquid preparation consisting essentially of at least the following two components, the first component ~~comprising~~ being 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component ~~comprising~~ being tyloxapol or polyethylene glycol monostearate, wherein said liquid preparation is formulated for ophthalmic administration.

**62. (Withdrawn-Currently amended)** A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative, to obtain an aqueous liquid preparation consisting essentially of at least the following two components, the first component ~~comprising~~ being 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component ~~comprising~~ being tyloxapol or polyethylene glycol monostearate, together with a preservative, wherein said liquid preparation is formulated for ophthalmic administration.

**63. (Cancelled)**

**64. (New)** An aqueous liquid preparation consisting essentially of:

- (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof,
  - (b) tyloxapol,
  - (c) boric acid,
  - (d) sodium tetraborate,
  - (e) EDTA sodium salt,
  - (f) benzalkonium chloride,
  - (g) polyvinylpyrrolidone, and
  - (h) sodium sulfite, and wherein said liquid preparation is formulated for ophthalmic administration.
- 

**65. (New)** The aqueous liquid preparation of claim 64, wherein (a) is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.

---

**66. (New)** The aqueous liquid preparation of claim 65, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.5 w/v % and the concentration of the tyloxapol is about 0.02 w/v %.

**67. (New)** The aqueous liquid preparation of claim 66, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.01 w/v %.

**68. (New)** The aqueous liquid preparation of claim 66, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.